Abbott Laboratories announced plans to spin off its Nutrition division to concentrate on higher-growth areas like diagnostics, medical devices, and pharmaceuticals. The company reported a 14.5% increase in Q3 revenue to $13.01 billion, driven mainly by its Diagnostics segment, boosted by the Exact Sciences acquisition. Abbott narrowed its 2026 adjusted EPS guidance to $5.50–$5.55, expecting the spin-off to enhance growth and profitability. Despite some near-term uncertainty and modest guidance, the outlook remains bullish for long-term double-digit growth after the separation.
Abbott Laboratories shares have fallen 4.10% to USD 98.49 on Pluang, reflecting some investor caution following the narrowed guidance and spin-off news. The stock's market cap stands at $177.28 billion, with a dividend yield of 2.46%. These figures are current as of Oct 22, 2026 01:01 WIB.
Abbott Laboratories reported Q3 2026 results with adjusted earnings per share of $1.42, matching estimates, and revenue of $13.01 billion, slightly above expectations. Despite 14.5% sales growth, the company lowered its 2026 sales growth forecast due...
Abbott posted a 14.5% increase in reported sales and 7.0% comparable sales growth for Q3 2026, with GAAP diluted EPS of $0.53 and adjusted EPS of $1.42. The company expanded its portfolio with FDA approvals for innovative products like the Libre Duo ...
Abbott announced plans to separate its Nutrition business into a standalone, publicly traded company by the end of 2027. The new Nutrition company will focus on the growing healthy nutrition market with $8.5 billion in annual sales and iconic brands ...
